Literature DB >> 19877728

Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Ercole Concia1, Anna Maria Azzini, Michela Conti.   

Abstract

Candida spp. are an increasing cause of bloodstream infections, and are associated with high morbidity and mortality in both neutropenic and non-neutropenic critically ill patients. Risk factors associated with candidaemia are diverse and include exposure to broad spectrum antimicrobial agents, mucosal colonization by Candida spp., indwelling vascular catheters, prior surgery and cancer chemotherapy. During the last 20 years, there has been an increasing incidence worldwide in invasive candidiasis, but differences in geographical epidemiology are emerging, in particular regarding a shift towards non-albicans species. This shift has been correlated with routine fluconazole prophylaxis adopted in some patients, and the intrinsic/acquired azole resistance of Candida spp., which represents a very real problem, in terms of both selecting the appropriate empirical therapeutic approach and making prophylactic choices.

Entities:  

Mesh:

Year:  2009        PMID: 19877728     DOI: 10.2165/11315500-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  91 in total

1.  Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.

Authors:  C J Clancy; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Clinical significance of Candida isolated from peritoneum in surgical patients.

Authors:  T Calandra; J Bille; R Schneider; F Mosimann; P Francioli
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality.

Authors:  H Alonso-Valle; O Acha; J D García-Palomo; C Fariñas-Alvarez; C Fernández-Mazarrasa; M C Fariñas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-22       Impact factor: 3.267

6.  Effects of nosocomial candidemia on outcomes of critically ill patients.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Am J Med       Date:  2002-10-15       Impact factor: 4.965

7.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  [Clinical aspects and prognosis of candidemia, a 6-year retrospective study].

Authors:  T Bregenzer; A C Evison-Eckstein; R Frei; W Zimmerli
Journal:  Schweiz Med Wochenschr       Date:  1996-10-26

9.  The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.

Authors:  J H van Burik; W Leisenring; D Myerson; R C Hackman; H M Shulman; G E Sale; R A Bowden; G B McDonald
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

10.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

View more
  19 in total

1.  A Risk Score for Fluconazole Failure among Patients with Candidemia.

Authors:  Luis Ostrosky-Zeichner; Rachel Harrington; Nkechi Azie; Hongbo Yang; Nanxin Li; Jing Zhao; Valerie Koo; Eric Q Wu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia.

Authors:  Marcella M Alsan; Nicolas C Issa; Sarah P Hammond; Danny A Milner; Daniel J DeAngelo; Lindsey R Baden
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

3.  Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Authors:  Pasquale De Bellis
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit.

Authors:  G Lo Cascio; R Koncan; G Stringari; A Russo; A Azzini; A Ugolini; M Ligozzi; E Polati; G Cornaglia; E Concia; V Schweiger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-13       Impact factor: 3.267

Review 6.  Histopathologic diagnosis of fungal infections in the 21st century.

Authors:  Jeannette Guarner; Mary E Brandt
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

7.  Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis.

Authors:  Anna R Huppler; Heather R Conti; Nydiaris Hernández-Santos; Toni Darville; Partha S Biswas; Sarah L Gaffen
Journal:  J Immunol       Date:  2014-01-17       Impact factor: 5.422

8.  Interaction of Candida albicans cell wall Als3 protein with Streptococcus gordonii SspB adhesin promotes development of mixed-species communities.

Authors:  Richard J Silverman; Angela H Nobbs; M Margaret Vickerman; Michele E Barbour; Howard F Jenkinson
Journal:  Infect Immun       Date:  2010-08-30       Impact factor: 3.441

Review 9.  Clinical aspects of invasive candidiasis in the surgical patient.

Authors:  Gabriele Sganga
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.